Palisade Bio (PALI)
Develops a once-daily oral PDE4 prodrug for ulcerative colitis and Crohn's disease.
Something off on this page? Send us feedback.
Develops PALI-2108, a once-daily oral PDE4 inhibitor prodrug intended for bacterial activation in the terminal ileum and colon for inflammatory bowel disease. With no approved products or product revenue, it operates as a clinical sponsor reliant on third parties and a Giiant license.
Develops PALI-2108, a once-daily oral PDE4 inhibitor prodrug for ulcerative colitis and Crohn's disease, designed for bacterial activation in the terminal ileum and colon. The approach aims to sustain local target inhibition while limiting systemic exposure and improving tolerability.
Operates as a lean clinical-stage sponsor, using consultants and relying on contract research organizations and other third parties to conduct and oversee trials. It holds worldwide rights to PALI-2108 and PALI-1908 from Giiant, with development, manufacturing, milestone and royalty obligations under the license.
Maintains no physical headquarters and has no approved products or product revenue. Future revenue depends on regulatory approval, product marketing, out-licensing or sublicensing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 23, 2026 | Oppenheimer | Initiate | Rating: — | |
| Jun 30, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $2 |
| Jun 30, 2026 | Oppenheimer | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $125.2M · Total debt $0 · Total assets $127.3M · Shareholders' equity $121.7M
- Revenue
- $500.0K
- Operating income
- −$11.7M
- Net income
- −$10.6M
No dividends on record.
| Institutions | ≈ 99.64% | 173.64M shares | |
|---|---|---|---|
| 126 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.24% | 3.91M shares | |
| 7 holders · as of Aug 21, 2026 | |||
| Strategic holders | 8.54% | 14.89M shares | |
| 1 holder · as of Dec 8, 2025 | |||
| Adds to | 110.42% | ||
174.27M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.42%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Janus Henderson Group PLCStrategic | 8.54% | 14.89M | filed Dec 8, 2025 |
Soleus Capital Management, L.P.Institution | 7.50% | 13.06M | as of Jun 30, 2026 |
Commodore Capital LPInstitution | 7.10% | 12.37M | filed May 15, 2026 |
B Group, Inc.Institution | 6.55% | 11.41M | as of Jun 30, 2026 |
Ameriprise Financial IncInstitution | 6.36% | 11.08M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 8, 2026 | Robert Jr. Baltera | director | +20,000 | $1.99 |
| Jul 9, 2026 | Robert Jr. Baltera | director | +25,000 | $1.96 |
| Jul 7, 2026 | John David Finley | director, officer: CEO, CFO | −146,798 | $2.07 |
| Jul 7, 2026 | Mitchell Lawrence Jones | officer: Chief Medical Officer | −51,880 | $2.05 |
| Jul 6, 2026 | Robert Jr. Baltera | director | +20,000 | $2.05 |
- AbbVie
The broadest approved UC/CD overlap through Skyrizi, Rinvoq and Humira.
- Johnson & Johnson
Multiple biologics address the same moderate-to-severe UC/CD treatment pool.
- Takeda (ADR)
Entyvio is an established gut-focused UC/CD biologic for the same patients.
- Eli Lilly
Omvoh brings an IL-23 option across moderate-to-severe UC and CD.
- Pfizer
Oral Velsipity and Xeljanz address moderate-to-severe UC.
- Bristol-Myers Squibb
Once-daily oral Zeposia addresses moderate-to-severe UC.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Palisade Bio | $1.60 | −5.33% | $293.3M | — | — | 586.7 | — |
| AbbVie | $264.77 | −0.17% | $468.77B | 74.8 | 17.4 | 7.3 | +10.2% |
| Johnson & Johnson | $268.34 | −0.32% | $648.72B | 31.2 | 22.6 | 6.6 | +6.6% |
| Takeda (ADR) | $18.82 | −0.71% | $60.30B | 52.9 | 59.9 | 2.0 | +4.2% |
| Eli Lilly | $1,152.13 | −1.54% | $1.10T | 39.3 | 28.2 | 13.8 | +47.7% |
| Pfizer | $27.92 | −0.04% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $61.24 | −1.62% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Median | 38.1 | 20.0 | 4.6 | +6.2% |